Tenaya Therapeutics, Inc. TNYA 深 滬
等待開盤 06-26 09:30:00 美东时间
0.71
-0.021
-2.86%
華盛通- 最 高0.7498
- 今 開0.7203
- 成交量 128.98万股
- 最 低 0.71
- 昨 收 0.7309
- 總市值 1.54亿
- 52周最高 2.35
- 市盈率 靜 --
- 換手率 0.59%
- 52周最低 0.5316
- 委 比 97.18%
- 總股本 2.17亿
- 歷史最高 32.00
- 量 比 0.54
- 振 幅 5.45%
- 歷史最低 0.36
- 每 手 1
- 風險率 0.36%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Tenaya Therapeutics To Report New Interim Data From Cohort 1 And 2 Of Ongoing MyPEAK-1 Phase 1b/2 Trial Of TN-201 Gene Therapy For Adults With MYBPC3-Associated Hypertrophic Cardiomyopathy On June 3
Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today
06-03 04:32
Tenaya Therapeutics' Gene Therapy Data Highlights Early Heart Rhythm Improvements
Tenaya reported early RIDGE-1 data showing reduced arrhythmias and favorable safety for TN-401 in PKP2-related ARVC patients.
05-15 22:11
Earnings Scheduled For May 6, 2026
Companies Reporting Before The Bell • Deluxe (NYSE:DLX) is expected to report q...
05-07 05:03
Tenaya Therapeutics Q1 EPS $(0.09) Misses $(0.06) Estimate, Sales $25.000M Beat $10.000M Estimate
Tenaya Therapeutics (NASDAQ:TNYA) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimate of $(0.06) by 50 percent. This is a 62.5 percent increase over losses of $(0.24) per share from
05-07 04:39
Tenaya Therapeutics Announces Acceptance Of Multiple Abstracts For Presentation At ASGCT Annual Meeting; To Feature New Clinical Data From Both Dose Cohorts Of RIDGE-1 Phase 1b/2 Trial Of TN-401 As Late-Breaking Oral Presentation
Readout to Include One-Year Cohort 1 Results and Early Cohort 2 Data; Webcast Conference Call Planned to Review RIDGE-1 Data at ASGCTAdditional Presentations at ASGCT Showcase Tenaya's Work with Patients to Advance Gene
04-27 20:32
Tenaya Therapeutics Q4 EPS $(0.12) Beats $(0.13) Estimate
Tenaya Therapeutics (NASDAQ:TNYA) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.13) by 9.09 percent. This is a 57.14 percent increase over losses of $(0.28) per share
03-12 04:10
美股牛股 | 传与OpenAI合作+CEO大规模增持，TTD大涨超18%；石油股SOC暴涨超37%
传与OpenAI合作+CEO大规模增持，TTD大涨超18%；中东局势加剧引油价狂飙！石油股SOC暴涨超37%>>
03-06 16:48
Tenaya Therapeutics Collaborates With Alnylam Pharmaceuticals To Discover Human Genetic Targets For Potential Development Of Disease-modifying Treatments For Cardiovascular Diseases
Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease,
03-05 21:34
美股牛股 | 矽晶电信飙升近30%，Q4营收同比大增17%；西南航空大涨18%
矽晶电信飙升近30%，Q4营收同比大增17%；摩丁制造大涨20%，分拆技术业务并与Gentherm合并，以优化公司结构；西南航空大涨18%，Q4每股收益及全年指引均超预期>>
01-30 18:27
Tenaya Therapeutics Issues Update On Clinical Development Programs And Outlines Strategic Priorities For 2026; Aims To Build On Positive 2025 Interim TN-201 Results In H1 2026
Aims to Build on Positive 2025 Interim TN-201 Results in First Half of 2026 with Longer-Term Follow-Up Data for Cohorts 1 and 2 from MyPEAK™-1 Trial of Adults with MYBPC3-Associated HCMExpects to Report
01-09 21:38
